The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD.
GlaxoSmithKline and Theravance have announced positive results from two Phase III studies, which showed that patients with Chronic Obstructive Pulmonary...
GlaxoSmithKline has announced that the European Commission has granted marketing authorisation for Incruse (umeclidinium) powder delivered by the Ellipta inhaler,...
GlaxoSmithKline and Innoviva announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta...
CHMP recommends change to authorisation for Relvar Ellipta in asthma.
GlaxoSmithKline plc and Theravance, Inc. announced that the European Commission has on 18 November 2013, granted marketing authorisation for Relvar...
GlaxoSmithKline plc and Theravance, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the FDA for a...
GlaxoSmithKline plc announced that the FDA has on 20 August 2014 approved Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily...
GlaxoSmithKline plc and Theravance, Inc. have announced that the FDA has on 18 December 2013, approved Anoro Ellipta a combination...
GlaxoSmithKline has announced that the FDA has approved Incruse Ellipta (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance...